Impacts of anticancer drug parity laws on mortality rates

Bibliographic Data

ID4589466
AuthorsYichen Shen (0000-0002-2533-8388, Waseda University, corresponding author), Harkuo Noguchi (0000-0002-4437-8238, Waseda University)
Year2021
Volume272
Pages113714
Publication date2021-03-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueSocial Science & Medicine (JOURNAL)
Journal identifiersISSN: 0277-9536 • E-ISSN: 1873-5347
PublisherElsevier BV (PUBLISHER)
DOI10.1016/j.socscimed.2021.113714
PMID33545495
OpenAlexW3122716714
LanguageEN
References cited47

This study investigates the impacts of anticancer drug parity laws on mortality rates in the United States using a difference-in-differences approach. Using data from 2004 to 2017 Compressed Mortality Files, we show that the anticancer drug parity laws reduce the mortality rate for head/neck malignant cancers but have no impact on malignant cancers of other types. We also rule out an insurance expansion channel that may influence the relationship between anticancer drug parity laws and malignant cancer mortality. Our results are robust to various specifications and falsification tests. Our findings imply that providing equal access to oral anticancer drugs is an effective tool for the prevention of premature mortality

Anticancer drug · Cancer drugs · Drug · Mortality rate · Parity (physics · Sociology · Demography · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access